PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model

PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model

While chimeric antigen receptor (CAR) T cell immunotherapy targeting CD19 has shown remarkable success in patients with lymphoid malignancies, the potency of CAR T cells in solid tumors is low so far. To improve the efficacy of CAR T cells targeting prostate carcinoma, we designed a novel CAR that r...

Full description

Bibliographic Details
Main Authors: Jamal Alzubi, Viviane Dettmer-Monaco, Johannes Kuehle, Niko Thorausch, Maximilian Seidl, Sanaz Taromi, Wolfgang Schamel, Robert Zeiser, Hinrich Abken, Toni Cathomen, Philipp Wolf
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:Molecular Therapy: Oncolytics
Subjects:
CAR T cells
prostate cancer
focal therapy
docetaxel
chemotherapy
combination therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770520300930

Internet

http://www.sciencedirect.com/science/article/pii/S2372770520300930

Similar Items